The US Food and Drug Administration (FDA) has granted 510(k) clearance to Cynosure to market SculpSure for non-invasive lipolysis of the abdomen.

Using patented technology, SculpSure is designed to reduce fat non-invasively by disrupting subcutaneous fat cells.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The versatile, hands-free, clinically proven and safe treatment device features a flexible applicator system to treat multiple anatomical areas of the body.

"SculpSure is the world’s first hyperthermic laser treatment for the non-invasive reduction of fat from the abdomen."

In addition, the device uses a 1,060nm laser, and can treat an anatomical area in approximately 25 minutes, offering desired results to patients without downtime or surgery.

Bass Plastic Surgery plastic surgeon Dr Lawrence Bass said: "SculpSure is the world’s first hyperthermic laser treatment for the non-invasive reduction of fat from the abdomen.

See Also:

"Subjects in our study saw a statistically significant reduction in adipose layer thickness, with more than 90% reporting they were satisfied with the treatment."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Cynosure CEO Michael Davin said: "The abdomen and flanks are two areas of the body that are often difficult to target with diet and exercise alone, so the fact that SculpSure can now effectively treat both of these regions is great news for consumers.

"It’s also a significant achievement for our company, demonstrating the initial breadth of our non-invasive fat reduction platform.

"We believe that SculpSure’s versatility and fast treatment time are key competitive advantages that will drive demand for the technology among aesthetic practitioners and their patients."

In May, SculpSure was cleared by the FDA for non-invasive lipolysis of the flanks. The company plans to launch the device in the US in the second half of this year.